39results about How to "Oral administration is convenient" patented technology

A super-porous aqueo-gel of an interpenetrating network polymer used for the orally applying system of protein polypeptide to suppress proteinase and break the close linking between epithelial cells contains two polymers: a cross-linked polymer and a cross-linked polyose polymer. Its preparing process includes such steps as mixing at least one unsaturated enylmonomer, at least one polyenyl cross-linking agent, a linear polyose polymer and a foaming agent to generate the super-porous aqueo-gel of semi-interpenetrating network polymer, and cross-linking with linear polyose.

The invention discloses an ultra-multiaperture hydrogel compound, making method and application in pharmacy. It contains cross-linked polymer and Carbomer. At least one unsaturated alkene monomer and polyene cross-linking agent polymerize to develop it. The making steps: mix at least one unsaturated alkene monomer, one polyene cross-linking agent, Carbomer and one foaming agent; the mixture develops it on the condition of polymerizing and foaming. It can be used in stomach floating preparation and protein polypeptide oral medicine supplying system.

The present invention relates to methods that facilitate the oral administration of active drugs to a patient. Specifically, the methods of the present invention may utilize compositions comprising an active drug and a gelling agent that provides an easily consumable gel dosage form and the active drug is homogenously mixed within the gel.

The invention discloses an oral prednisone time-selecting release preparation and a preparation method thereof. The oral prednisone time-selecting release preparation provided by the invention mainly consists of 0.3-5 parts of prednisone and derivatives thereof, 10-50 parts of glyceryl behenate and 3-30 parts of hydroxypropyl cellulose, and can further contain a disintegrating agent and other pharmaceutically acceptable excipients. The preparation method is as below: extruding tablet cores or granules containing the drug according to the formula by a tablet press or a dry granulator; and coating the tablet cores or particles containing the drug by a coating pan or a fluidized bed to attach the coating film to the tablet cores or particles containing the drug, so as to obtain the oral prednisone time-selecting release preparation. The oral prednisone time-selecting release preparation provided by the invention can achieve a good balance between the biological rhythm of the patients and the curative effects, and is safer, more convenient and effective compared with a traditional preparation. The oral prednisone time-selecting release preparation is prepared by an extrusion-coating process, which is simple for operation, and the obtained time-selecting release preparation has the advantages of drug stability and high reproducibility.

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

The invention is a polypeptide protein type oral nano granular preparation. It uses polymer or amphiphatic compound as coating material, and uses the hydrogenous bonds formed between the surfactants absorbed on the interface of the coating material and the oil-water, for examples, the amido in the swelling chitosan molecule in the chitosan coating polyester nano granule and the oxygen atom or the alcohol hydroxyl in the hydrophilic ehenoxy group form the hydrogenous bonds to make it; or the chitosan directly makes the gelation reaction with the multivalent anions to make the nano-granular preparation.

The invention provides a proteolytic targeting chimeric body, a prodrug molecule for improving oral bioavailability of the proteolytic targeting chimeric body and application thereof. According to thetechnical scheme, a novel PROTAC degradation agent compound is developed on the basis of a ribociclib derivative and a CRBN ligand. Small molecules can effectively degrade CDK2/4/6 and compounds thereof in malignant melanoma at the same time; the cell cycle can be quickly reset, and apoptosis of various cancer cells, especially melanoma cells, can be induced. A mechanism should be explained as that CDK 2/4/6 deficiency may lead to synthetic lethal effects of malignant melanoma in the presence of a compound. The results show that the combination of CDK2/4/6 is expected to become a kinase target for treating solid tumors. In addition, the invention also develops a prodrug with high oral bioavailability for the first time, and is convenient for oral administration in animal tests. A universal solution is provided for oral administration of PROTAC molecules with CRBN ligands.

In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight.

The present invention relates to the novel medicinal use of dually acting compounds capable of inhibiting neutral endopeptidase (=NEP) and human soluble endopeptidase (=hSEP) in the prophylaxis and/or treatment of sexual dysfunction in mammals and humans.

An oral microemulsion of elemene is disclosed. The microemulsion is made of elemene, surfactant, cosurfactant and water or buffer solutions with pH 5˜8. Said surfactant is selected form tweens, polyoxyethylene castor oils, polyethylene glycol stearates and mixture thereof. Said cosurfactant is selected from ethanol, 1,3-propanediol, glycerol and mixture thereof. The concentration of elemene in the microemulsion is 1˜5 g/100 ml. The ratio of elemene, surfactant and cosurfactant is 1˜5(weight):1˜40(weight):1˜40(volume), wherein the unit of weight/volume is g/ml.

The invention discloses a Remdesivir tablet and a preparation method thereof. The tablet comprises a tablet core and a thin-film coating layer, wherein the tablet core comprises the following ingredients in parts by weight: 50-65% of Remdesivir, 4-7% of disintegrating agent, 4-7% of binding agent, 0.7-1.2% of lubricating agent, 0.1-0.9% of pH conditioning agent and the balance of filling agent, wherein the thin-film coating layer comprises the following ingredients: a coating material of a gastric-dissolved thin-film coating layer or the coating material of an enteric-coated thin-film coating layer, and the pH regulator is an organic acid type, a high-polymerization type or an alkalizer. The prepared Remdesivir tablet has good long-term stability and high blood concentration.

The invention discloses a butyl phthalide medicinal composite, which comprises butyl phthalide and silicon dioxide according to a mass ratio of 0.1-4:1. The preparation method comprises the following steps: weighing butyl phthalide and silicon dioxide, spraying butyl phthalide into silicon dioxide powder, and evenly mixing to obtain the powdery butyl phthalide medicinal composite. At the same time, the invention also discloses a sustained-release preparation of the butyl phthalide medicinal composite. The sustained-release preparation is characterized in that the butyl phthalide medicinal composite is taken as the active component, which is wrapped by one or more pharmaceutically-acceptable sustained-release coating materials. The preparation method is simple, the preparation time is short, the cost is low, and the preparation method is economic. The prepared medicinal composite has the advantages that the drug volatilization is effectively controlled, the stability is high, the drug loading capacity is large, the volume is small, and the dosage form is convenient for oral taking. The shortages of conventional commercial oral butyl phthalide preparations in clinic are overcome.

The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process for preparation thereof.

A mucosa adhesive nanoparticle for medicine, food and cosmetics is prepared from skeleton (alkyl polyacrylate, alkyl polymethylacrylate, or polycyanoacrylate) and coating (mucosa adhesive polymer) through dissolving the coating, adding skeleton and trigger, heating while reaction, continuous reaction and purifying.

The invention discloses metal organic framework nanoparticles for oral protein administration and a preparation method of the metal organic framework nanoparticles, and belongs to the technical field of pharmaceutics. The metal organic framework nanoparticles provided by the invention can promote oral absorption of protein/polypeptide with the molecular weight of at most 10000 Daltons. The metal organic framework nano-particle is prepared by loading a nano-scale acid-resistant metal organic framework with a small molecule protein/polypeptide drug through hydrophobic interaction and modifying a targeting molecule on the surface of the nano-scale acid-resistant metal organic framework. The porous acid-resistant metal organic framework shows high drug loading capacity and strong protectiveness to protein, and shows good biocompatibility and sustained and controlled release kinetics in vivo. The targeting molecule can target a receptor on an intestinal epithelial cell membrane, the problem that the permeation efficiency of protein in an intestinal epithelial cell layer is extremely low is solved, and the oral bioavailability of the protein is improved. The preparation method is simple and convenient, the production cost is low, and painless, controlled-release and convenient protein oral administration is expected to be realized.

Disclosed is a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2′,6,6′-tetraisopropyl-4,4′-biphenol, a solvent, and an antioxidant, among others.

A stable solvent-based composition is described which is particularly useful in warm blooded animals such as dogs. The composition comprises a therapeutically effective amount of carprofen, one or more polyols, one or more stabilising agents and optionally, one or more co-solvents.